HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Residual Neoplasm

Remnant of a tumor or cancer after primary, potentially curative therapy.
Also Known As:
Neoplasm, Residual; Minimal Disease, Residual; Residual Disease, Minimal; Residual Tumour; Cancer, Residual; Minimal Residual Diseases; Residual Cancers; Residual Minimal Disease; Residual Minimal Diseases; Residual Neoplasms; Residual Tumors; Residual Tumours; Tumour, Residual; Minimal Residual Disease; Residual Cancer; Residual Tumor
Networked: 9897 relevant articles (957 outcomes, 854 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasms (Cancer)
2. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
3. Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
4. Leukemia
5. Neoplasm Metastasis (Metastasis)

Experts

1. Wang, Yu: 50 articles (10/2022 - 05/2013)
2. Huang, Xiao-Jun: 47 articles (10/2022 - 07/2008)
3. Xu, Lan-Ping: 40 articles (10/2022 - 07/2008)
4. Liu, Kai-Yan: 37 articles (10/2022 - 07/2008)
5. Chen, Huan: 36 articles (01/2022 - 07/2008)
6. Pui, Ching-Hon: 36 articles (01/2022 - 06/2002)
7. Zhang, Xiao-Hui: 35 articles (10/2022 - 07/2012)
8. Schrappe, Martin: 32 articles (01/2021 - 12/2002)
9. Yan, Chen-Hua: 31 articles (01/2022 - 10/2013)
10. Han, Wei: 31 articles (01/2022 - 07/2012)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Residual Neoplasm:
1. blinatumomabIBA
2. Rituximab (Mabthera)FDA Link
3. Imatinib Mesylate (Gleevec)FDA Link
4. Monoclonal AntibodiesIBA
5. Biomarkers (Surrogate Marker)IBA
6. venetoclaxIBA
7. Cisplatin (Platino)FDA LinkGeneric
8. Messenger RNA (mRNA)IBA
9. VaccinesIBA
10. Cyclophosphamide (Cytoxan)FDA LinkGeneric

Therapies and Procedures

1. Therapeutics
2. Drug Therapy (Chemotherapy)
01/01/2022 - "This remarkable success stems from the progressive improvement in the efficacy of risk-adapted multiagent chemotherapy regimens with effective central nervous system (CNS) prophylaxis via well-designed randomized clinical trials conducted by international collaborative consortia, enhanced supportive care measures to decrease treatment-related mortality, in-depth understanding of the genetic basis of ALL, and refinement in treatment response assessment through serial minimal residual disease (MRD) monitoring (Pui et al., 2015) [3]. "
09/01/2013 - "Most cooperative groups previously used morphological clearance of blasts in blood and marrow during the initial phases of chemotherapy as a primary factor for risk group allocation; however, this has largely been replaced by the detection of minimal residual disease (MRD). "
03/01/2005 - "Such molecular information on pathogenesis has facilitated accurate diagnosis, the development of pathogenesis-targeted drug therapy, and most recently the application of molecular techniques for monitoring minimal residual disease after successful therapy. "
04/01/2022 - "The complete remission rate of bone marrow cytology after induction of 1 course of chemotherapy (84.7% vs 73.1%, P=0.155), and minimal residual disease detection (MRD) negative (42.3% vs 41.4%, P=0.928) in the 2015 regimen group were not statistically different than those in the 2006 regimen group. "
01/01/2021 - "The probability of achieving complete remission/complete remission with incomplete hematologic recovery (CR/CRi) and minimal residual disease (MRD)-negativity for InO relative to chemotherapy was also investigated. "
3. Radiotherapy
4. Stem Cell Transplantation
5. Hematopoietic Stem Cell Transplantation